Pharmaceutical Preparations · DE · CIK 1796280
Develops cancer therapies countering resistance mechanisms in hormone-dependent cancers, precision oncology, and tumor dependencies
Comparable business profile · signals at a glance
In the 90 days to Feb 24, 2026: 4 sold $1.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 24, 2026 | Piscitelli DominicChief Financial Officer | Sell | 52,000 | $13.51 | $703K |
| Jan 16, 2026 | Heyman Richard A.Director | Sell | 3,500 | $12.00 | $42K |
| Jan 16, 2026 | Heyman Richard A.Director | Sell | 3,200 | $12.00 | $38K |
| Dec 16, 2025 | Chacko JacobPRESIDENT AND CEO | Sell | 33,374 | $9.06 | $302K |
| Dec 16, 2025 | Piscitelli DominicChief Financial Officer | Sell | 10,720 | $9.06 | $97K |
| Dec 16, 2025 | Multani Pratik SChief Medical Officer | Sell | 10,720 | $9.06 | $97K |
| Oct 6, 2025 | Chacko JacobPRESIDENT AND CEO | Sell | 37,461 | $12.32 | $462K |
| Oct 6, 2025 | Piscitelli DominicChief Financial Officer | Sell | 11,000 | $14.52 | $160K |
| Oct 1, 2025 | Chacko JacobPRESIDENT AND CEO | Sell | 53,001 | $12.05 | $639K |
| Sep 30, 2025 | Chacko JacobPRESIDENT AND CEO | Sell | 34,538 | $12.01 | $415K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.